@article{2999631,
    title = "Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors",
    author = "Dimopoulou, D. and Spyridis, N. and Vartzelis, G. and Tsolia, M.N. and Maritsi, D.N.",
    journal = "Arthritis and Rheumatology",
    year = "2022",
    volume = "74",
    number = "2",
    pages = "365-366",
    publisher = "John Wiley and Sons Inc",
    issn = "2326-5191, 2326-5205",
    doi = "10.1002/art.41977",
    keywords = "adalimumab;  antirheumatic agent;  etanercept;  methotrexate;  tumor necrosis factor inhibitor, adolescent;  adverse event;  arthralgia;  disease exacerbation;  fatigue;  female;  headache;  human;  injection site reaction;  juvenile rheumatoid arthritis;  male;  myalgia;  prevention and control;  young adult, Adalimumab;  Adolescent;  Antirheumatic Agents;  Arthralgia;  Arthritis, Juvenile;  BNT162 Vaccine;  COVID-19;  Disease Progression;  Etanercept;  Fatigue;  Female;  Headache;  Humans;  Injection Site Reaction;  Male;  Methotrexate;  Myalgia;  SARS-CoV-2;  Tumor Necrosis Factor Inhibitors;  Young Adult"
}